VolitionRx CEO Reports Routine RSU Tax Withholding on Form 4
Rhea-AI Filing Summary
Form 4 discloses that Salvatore T. Butera, CEO of Volition Veterinary and an officer of VolitionRx (VNRX), had 6,393 common shares automatically withheld on 01-Aug-2025 (code “F”) to cover taxes due on the vesting of 23,377 restricted stock units received in lieu of cash compensation. The withheld shares were cancelled by the company; neither the insider nor VolitionRx executed an open-market sale. After the transaction Mr. Butera owns 303,524 shares directly and 99,350 shares jointly with his spouse, keeping his overall economic stake largely intact. No derivative securities were transacted. Because the action was tax-related and not a discretionary sale or purchase, it carries limited insight into management’s view of valuation, but it does confirm the continued equity alignment of a key executive.
Positive
- No open-market sale; shares were cancelled for taxes, avoiding potential selling pressure.
Negative
- Slight reduction in insider ownership (-6,393 shares) as a result of withholding, though economically immaterial.
Insights
TL;DR: Routine tax withholding; insider still holds ~403k shares, no open-market activity—neutral signal.
The Form 4 shows a non-discretionary share cancellation to satisfy tax obligations tied to RSU vesting. Such “F” code events are mechanically triggered and do not indicate sentiment. Post-event ownership remains substantial, preserving alignment with shareholders. The lack of derivative activity or open-market sales suggests no adverse liquidity concerns, but likewise offers no bullish signal. Given the small share count relative to VolitionRx’s 60 m+ outstanding shares, market impact is negligible.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 6,393 | $0.64 | $4K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 23,377 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. These shares of common stock are jointly owned by the reporting person and his spouse.
FAQ
What did VNRX insider Salvatore Butera report on Form 4?
Were any options or other derivatives exercised?
Is this Form 4 filing impactful for VNRX investors?